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INTRODUCTION 
Transdermal drug delivery systems (TDDS), also known as   
patches, are dosage forms designed to deliver a 
therapeutically effective amount of drug across a patient’s 
skin. In order to deliver therapeutic agents through the 
human skin for systemic effects, the comprehensive 
morphological, biophysical and physicochemical  properties 
of the skin are to be considered. Transdermal delivery 
provides a leading edge over injectables and oral routes by 
increasing patient compliance and avoiding first pass 
metabolism espectively1. Transdermal delivery not only 
provides controlled, constant administration of the drug, but 
also allows continuous input of drugs with short biological 
half-lives and eliminates pulsed entry into systemic 
circulation, which often causes undesirable side effects. Thus 
various forms of Novel drug delivery system such as 
Transdermal drug delivery systems, Controlled release 
systems, Transmucosal delivery systems etc. emerged. 
Several important advantages of transdermal drug delivery 
are limitation of hepatic first pass metabolism, enhancement 
of therapeutic efficiency and maintenance of steady plasma 
level of the drug. The first Transdermal system, Transderm-
SCOP was approved by FDA in 1979 for the prevention of 
nausea and vomiting associated with ravel, particularly by 
sea. The evidence of percutaneous drug absorption may be 
found through measurable blood levels of the drug, 
detectable excretion of the drug and its metabolites in the 
urine and through the clinical response of the patient to the 
administered drug therapy.2 The common ingredients which 
are used for the preparation of TDDS are as follows. 3 
 Drug: Drug is in direct contact with release liner.Ex: 
Nicotine, Methotrexate and Estrogen. 
 Liners: Protects the patch during storage. Ex: polyester 
film.  
 Adhesive: Serves to adhere the patch to the skin for 
systemic delivery of drug. 
Ex: Acrylates, Polyisobutylene, Silicones. 
 Permeation enhancers: Controls the Release of the 
drug. Ex: Terpenes, Terpenoids, Pyrrolidones.Solvents 
like alcohol, Ethanol, Methanol.Surfactants like 
Sodium Lauryl sulfate, Pluronic  F127, Pluronic F68. 
 Backing layer: Protect patch from outer environment. 
Ex: Cellulose derivatives, poly vinyl alcohol, 
Polypropylene Silicon rubber. 
Advantages of Transdermal Drug Delivery System 
(TDDS) 
The advantages of transdermal delivery over other delivery 
systems are as follows: 
1. Avoidance of first pass metabolism of drugs. 
2. Reduced plasma concentration levels of drugs, with 
decreased side effects. 
3. Reduction of fluctuations in plasma levels of drugs, 
Utilization of drug candidates with short half-life and 
low therapeutic index. 
4.  Easy elimination of drug delivery in case of toxicity.  
5.  Reduction of dosing frequency an enhancement of 
patient compliance.  
6. Transdermal medications deliver a steady infusion of a 
drug over and extended period of time. Adverse effects 
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or therapeutic failure frequently associated with 
intermittent dosing can also be avoided. 
7. Transdermal delivery can increase the therapeutic value 
of many drugs via avoiding specific problems associated 
with the drug. E.g. GI irritation, lower absorption, 
decomposition due to ‘hepatic first pass’ effect.  
8. Due to above advantage, it is possible that an equivalent 
therapeutic effect can be elicited via transdermal drug 
input with a lower daily dose of the drug than is 
necessary, if e.g. the drug is given orally. 
9. The simplified medication regimen leads to improved 
patient compliance and reduced inter and intra-patient 
variability. 
Limitation of TDDS 
The drug must have some desirable physicochemical 
properties for penetration through stratum corneum and if the 
drug dosage required for therapeutic value is more than 10 
mg/day, the transdermal delivery will be very difficult if not 
impossible.Skin irritation or contact dermatitis due to the 
drug, excipients and enhacers of the drug used to increase 
percutaneous absorption is another limitation. Clinical need 
is another area that has to be examined carefully before a 
decision is made to develop a transdermal product The 
barrier function of the skin changes from one site to another 
on the same person, from person to person and with age.  
Limitations for a drug substance to be incorporated into 
a transdermal delivery system are: - 
 Heavy drugs molecules (>500 Da) usually difficult to 
penetrate the stratum cornea. 
 Drugs with very low or high partition coefficient fail 
to reach blood circulation. 
 Drugs that are highly melting can be given by this 
route due to their low solubility both in water and fat. 3 
 Many approaches have been attempted to deliver 
medicament across skin barrier and enhance the 
efficacy.  
The major considerations for enhancing transdermal 
delivery are physical enhancers (ultrasound, iontophoresis, 
electroporation, magnetophoresis, microneedle), vesicles, 
particulate systems (liposome, niosome, transfersome, 
microemulsion, solid lipid nanoparticle) and chemical 
enhancers (sulphoxides, azones, glycols, alkanols, terpenes 
etc.).4  
 
Figure 1: Crystal reservoir technology has resulted in smaller patches with a more controlled and sustained drug release 
 
Figure 2: Sustained release is facilitated through the consistent rejuvenation of drug molecules at the surface of skin 
Along with A number of drugs may be administered by 
transdermal route. Transdermal drug absorption markedly 
alters drug kinetics and depends on a several parameters 
including the following- 
 Medicament application site 
 Thickness and integrity of the stratum cornea 
epidermidis. 
 Size of the molecule that is to be administered. 
 Permeability of the membrane for the transdermal drug 
delivery. 
 Hydration state of skin. 
 pH of the drug. 
 Drug metabolism by skin flora. 
 Lipid solubility. 
 Drug depot in skin. 
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 Blood flow alteration in the skin by additives and body 
temperature 
The toxic effect of the drug and problem in limiting drug 
uptake are major considerable potential for transdermal 
delivery systems, especially in children because skin 
thickness and blood flow in the skin usually vary with age. 
The increased blood supply in the skin along with thinner 
skin has significant effects on the pharmacokinetics of 
transdermal delivery for children. In some situations this may 
be an advantageous, while in others systemic toxicity may 
occur. This was observed after using scopolamine patches 
that are used to prevent motion sickness, a eutectic mixture 
of local anesthetics (EMLA) cream used to minimize the 
pain, corticosteroid cream applied for its local effect on skin 
maladies. Episodes of systemic toxic effects, including some 
fatalities in children have been documented with each of 
these, often secondary to accidental absorption through 
mucous membranes5. 
 Limitations for a drug substance to be incorporated into 
a transdermal delivery system are: - 
 Heavy drugs molecules (>500 Da) usually difficult to 
penetrate the stratum cornea. 
 Drugs with very low or high partition coefficient fail to 
reach blood circulation. 
 Drugs that are highly melting can be given by this route 
due to their low solubility both in water and fat 1.  
Many approaches have been attempted to deliver 
medicament across skin barrier and enhance the efficacy. 
The major considerations for enhancing transdermal delivery 
are physical enhancers (ultrasound, iontophoresis, 
electroporation, magnetophoresis, microneedle), vesicles, 
particulate systems (liposome, niosome, transfersome, 
microemulsion, solid lipid nanoparticle) and chemical 
enhancers (sulphoxides, azones, glycols, alkanols, terpenes 
etc.). 6  
1. Tdds Classification Based On Their Technical 
Sophistication  
a) Rate pre-programmed drug delivery syste 
b) Activation modulated drug delivery system 
c) Feedback regulated drug delivery system 
d) Carrier based drug delivery system 
A) Rate Pre Programmed Drug Delivery System 
It involves the system design that delivers medicaments by 
controlling molecular diffusion of drug molecules across the 
skin barrier within or surrounding the delivery system.  
1. Polymer membrane permeation controlled drug 
delivery system- 
It involves the system in which the drug is enclosed within a 
drug reservoir. This is covered by the semi permeable 
membrane of polymer that regulates the release and having a 
specific permeability. There are some potential development 
with process of membrane permeation are as microporous 
membrane permeation controlled gastrointestinal delivery 
device, gastric fluid resistance intestinal targeted controlled 
release gastrointestinal device and gel diffusion controlled 
drug delivery system.7  
 2. Polymer matrix diffusion controlled drug delivery 
system- 
It is developed by dispersing drug particles in carrier matrix 
(in a homogenous manner) that is rate controlling i.e. 
NitroDur. It is designed for application onto intact skin for 
24 hrs that provide consistence transdermal infusion of 
nitroglycerine. 8  
3. Microreservoir partitioned controlled drug delivery 
system- 
It involves dispersion of micro particles of suspension of 
drug (aqueous in nature) in a polymer using high energy 
dispersion. e.g. Syncromate implant. Engineered to deliver 
subdermal administration of norgestomet.8  
B) Activation Modulated Drug Delivery System 
This type of delivery system can be achieved by- 
1-Physical means 
 Osmotic pressure activated drug delivery system. 
 Hydrodynamic pressure controlled drug delivery 
system. 
 Vapour pressure activated drug delivery system. 
 Mechanically activated drug delivery system. 
 Magnetically activated drug delivery system. 
 Electrically activated drug delivery system. 
 Ultrasound activated drug delivery system. 
 Hydration activated drug delivery system.  
2-Chemical means 
 pH activated drug delivery system 
 Ion activated drug delivery system 
 Hydrolysis activated drug delivery system  
3-Biochemical means 
 Enzymes activated drug delivery system 
C) Feedback Regulated Drug Delivery System 
The release of the drug molecules from the transdermal 
system is facilitated by a agent that triggers the release of 
drug, such as biochemicals in the body and also regulated by 
its concentration through some feedback mechanism. 
 Bio-erosion regulated drug delivery system. 
 Bio-responsive drug delivery system. 
 Self regulated drug delivery system. 9  
D) Carrier Based Drug Delivery System 
Colloidal particulates carrier system: 
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This involves vesicular system like hydrogels, liposomes, 
niosomes, nanocapsules, nanoparticles, polymeric 
complexes, microspheres, nanoerythrosomes, 
transferosomes, dendrimers, aquasomes, etc. 
RECENT TECHNIQUES FOR ENHANCING TDDS 
A) STRUCTURE-BASED ENHANCEMENT 
TECHNIQUES: 
1.  Transdermal Patches 
A transdermal patch or skin adhesive patch is that device 
which is loaded with drug candidate and usually applied on 
the skin to transport a specific dose of medication across the 
skin and into the blood circulation. 10  
The adhesive serves two functions: It is glue in nature that 
keeps the patch adhered to the skin, and it acts as the 
suspension that holds the drug. The problems associatedwith 
this is the concentration of the drug within the adhesive 
directly affects the "stickyness" of the adhesive so if the large 
quantities of drug is to be administered , either the size of the 
patch have to be increased or the patch needs to be reapplied 
again and again. Several pharmaceuticals usually combined 
with substances, like alcohol, within the patch to improve 
their penetration via skin in order to improve absorption. 11 
Components of Transdermal Patch:- 
Liner - Protects the patch during storage. The liner should be 
removed before its use.                                                                                                                            
Drug-Drug solution is in direct contact with release liner. 
Adhesive- It serves to adhere the components of the patch 
together along with adhering the patch to the skin. E.g.- 
Acrylic, polyisobutylene (PIB), and silicone are the 
adhesives have many pharmaceutical applications. For 
applications in which the adhesive, the drug, and perhaps 
enhancers are compounded, the selection of a PSA is more 
complex (e.g., a matrix design).                         
Membrane- It controls the release of the drug from the 
reservoir and multi-layer     patches.                                                                                                               
Backing- The film protects the patch from the outer 
environment 12-13. 
 
 
Figure 3: Different parts of Transdermal Patch 
Requirements for pressure-sensitive adhesives (PSAs) 
Several classes of PSAs are used for skin contact application 
include acrylics, polyisobutylene and silicone polymers. 16 
The functional properties of PSAs such as tackyness, 
adhesive property, release force, and cohesive strength as 
well as adhesive formulations having attributes such as 
enhanced drug flux and skin friendliness. A PSA must be 
able to performance effectively under a wide range of 
temperatures, humidity levels, and application frequency 
(from 24 hrs for some products to one week for others). The 
effects of mechanical stresses (e.g., stretching) as well as 
skin irritation and sensitization also must be considered. 21 
The human studies of various commercially available 
transdermals are examined and reported to assess the relative 
performance capabilities of each type of transdermal 
design.24 Monolithic TTS was fabricated in PSAs- (a) 
terpolymer (PSA1) of 2-ethylhexyl acrylate, methyl 
methacrylate, and acrylic acid, (b) copolymer (PSA2) of 2-
ethylhexyl acrylate, methyl methacrylate, acrylic acid, and 
vinyl acetate, and (c) Eudragit E100 pressure sensitive 
adhesive (PSA3). The transport of nicorandil via skin can be 
achieved by the skin permeation enhancer i.e. N-methyl-2-
pyrrolidone (NMP) was investigated at different 
concentrations (5%) in PSAs 17  
2. Microfabricated Microneedles 
These are the devices which are having the features of both 
the hypodermic needle and transdermal patch that can deliver 
the drug that transports the drug effectively across the 
memberane. The systems consists of a drug reservoir and a 
some projections (microneedles) extending from the 
reservoir, these helps in penetrating the stratum cornea and 
epidermis to deliver the drug. 
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Figure 4: Delivery site for microneedle technology. (a) Hollow microneedles with applied formulation; (b) Solid 
microneedles Microneedles are tiny and very sleek devices that are manufactured by the silicon etching technology and micro-
mechanical system manufacturing (MEMS) technique, which do not penetrate deep enough into the skin to reach up to the 
nerve endings and thus there is no pain sensation during the microneedles insertion into the skin. There are number of delivery 
approaches that have been employed to use the microneedles for TDDS. These includes-  
Poke with patch approach- Involves piercing into the skin 
followed by application of the drug patch at the site of 
treatment. 
Coat and poke approach- Needles coated with the drug are 
inserted into the skin and release of medicament is then 
occurs by dissolution. 
Biodegradable microneedles- Involves encapsulation of the 
drug within the biodegradable, polymeric microneedles, 
which is then inserted into the skin. 
Hollow microneedles- Involves injecting the drug through 
the needle with a hollow bore. 30 
3.Macroflux 
These are devices having an area of around 8cm as well as 
300 micro projections per cm2 with the length of individual 
micro projection less than 200Î¼m. Three types of 
Macroflux have been designed . They include, Dry-Coated 
Macrofluxsystem-this is used for short period delivery that 
consists microprojection array coated with medicament that 
adhered to a elastic polymer adhesive backing . 
4. Metered-Dose Transdermal Spray (Mdts) 
It is a liquid preparation in the form of solution that are used 
topically which is made up of a vehicle that is volatile come 
non volatile in nature, which consists the completely 
dissolved medicament in solution . The use of MDTS 
reaches the sustained level and better permeation of the drug 
via skin. The MDTS has the following potential advantages: 
 It improves delivery potential without skin irritation due 
to its non-occlusive nature. 
 Increased acceptability. 
 Dose flexibility 
 Simple manufacture 1. 
B) ELECTRICALLY-BASED ENHANCEMENT 
TECHNIQUES: 
1. Iontophoresis  
It involves passing of current (few milliamperes) to skin 
limited to a certain area using the electrode remains in 
contact with the formulation which is to be administered. 
Pilocarpine delivery can be taken as example to induce sweat 
in the diagnosis of cystic fibrosis and Iontophoretic delivery 
of lidocaine is considered to be a nice approach for rapid 
onset of anesthesia. 18, 19 
2. Ultrasound 
In this technique, there is a mixing of drug substance with a 
coupling agent (usually with gel, cream or ointment) that 
causes ultrasonic energy transfer from the system to the skin. 
This involves rupturing the lipids present in stratum cornea, 
which allows the medicament to permeate via biological 
barrier. 
3. Photomechanical Waves 
Photomechanical waves significantly led to the stratum 
cornea highly permeable to drug substance through a 
possible permeabilisation mechanism due to development of 
transient channels. 
4. Electroporation 
 It this method, short and high-voltage electrical pulses are 
applied to the skin thus the diffusion of drug is improved 
with the increasing permeability. The electrical pulses are 
considered to form small pores in the stratum cornea, 
through which transportation of drug occurs. For the safe and 
painless administration, the electrical pulses introduced by 
closely spaced electrodes to reserved the electric field within 
the stratum cornea. 18, 20, 21, 22 
5.Electro-Osmosis 
To the porous membrane which is having some charge, a 
voltage difference is applied to it, thus a bulk fluid or volume 
flow takes place with no concentration gradients. This 
process is known as electro-osmosis. 
C).VELOCITY BASED ENHANCEMENT 
TECHNIQUES: 
1. Needle-Free Injections 
 Intraject  
 Implaject  
 Jet Syringe 
 Iject  
 Mini-ject  
2. Powderject Device 
The solid drug particles are propelled across the skin with the 
aid of high-speed gas flow. This consists of a gas canister 
that allows helium gas at high pressure to enter a chamber at 
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the end of which drug cassette containing powdered drug 
between two polycarbonate membranes. After release, the 
instantaneous rupturation of both membranes usually seen 
that results in the gas to expand quickly which forms a strong 
motion like a wave that travels down the nozzle. This takes 
place at the speed of 600-900 m/s. 
D) OTHER ENHANCEMENT TECHNIQUES: 
1. Transfersomes- 
This device penetrates the skin barrier along the skin 
moisture gradient. Transfersome carriers can create a drug 
depot in the systemic circulation that is having a high 
concentration of drug. Transfersomes contain a component 
that destabilizes the lipid bilayers and thus leading to the 
deformable vesicles. 
2. Medicated Tattoos- 
Med-Tats is a modification of temporary tattoo which 
contains an active drug substance for trandermal delivery. 
This technique is useful in the administration of drug in those 
children who are not able to take traditional dosage forms. 
3. Skin Abrasion- 
This involves direct removal or disruption of the upper layers 
of the skin to provide better permeation of topically applied 
drug substance. In general, one approach is adopted to 
creates micro channels in the skin by eroding the 
impermeable outer layers with sharp microscopic metal 
granules is generally known as Microscissuining. 
4. Controlled Heat Aided Drug Delivery (CHADD) 
System- 
It facilitates the transfer of drug substance to the blood 
circulation by applying heat to the skin that increases the 
temperature and ultimately led to increase in 
microcirculation and permeability in blood vessel. CHADD 
system consists of small unit that is used for heating purpose, 
placed on top of a conventional patch device. An oxidation 
reaction occurs within the unit which tends to form heat of 
limited intensity and duration.  
5. Laser Radiation- 
This involves the exposure of the skin to the laser beam that 
results in the ablation of the stratum cornea without 
damaging the epidermis which remains in contact with it. 
Removal of the stratum cornea by this technique is 
considered to improve the delivery of lipophilic and 
hydrophilic drugs. 
6. Magnetophoresis- 
The effect of magnetic field on diffusion flux of drug 
substance was found to enhance with increasing applied 
strength. 1 
TYPES OF TRANSDERMAL PATCHES: 
4-8 
a) Single layer drug in adhesive: 
In this type the adhesive layer contains the drug. The 
adhesive layer not only serves to adhere the various layers 
together and also responsible for the releasing the drug to the 
skin. The adhesive layer is surrounded by a temporary liner 
and a backing.  
b) Multi -layer drug in adhesive: 
This type is also similar to the single layer but it contains a 
immediate drug release layer and other layer will be a 
controlled release along with the adhesive layer. The 
adhesive layer is responsible for the releasing of the drug. 
This patch also has a temporary liner-layer and a permanent 
backing. 
c) Vapour patch:  
In this type of patch the role of adhesive layer not only serves 
to adhere various layers together but also serves as release 
vapour. The vapour patches are new to the market, 
commonly used for releasing of essential oils in 
decongestion. Various other types of vapor patches are also 
available in the market which are used to improve the quality 
of sleep and reduces the cigarette smoking conditions.  
d) Reservoir system: 
In this system the drug reservoir is embedded between an 
impervious backing layer and a rate controlling membrane. 
The drug releases only through the rate controlling 
membrane, which can be micro porous or non porous. In the 
drug reservoir compartment, the drug can be in the form of a 
solution, suspension, gel or dispersed in a solid polymer 
matrix. Hypoallergenic adhesive polymer can be applied as 
outer surface polymeric membrane which is compatible with 
drug. 
e) Matrix system: 
i. Drug-in-adhesive system: 
In this type the drug reservoir is formed by dispersing the 
drug in an adhesive polymer and then spreading the 
medicated adhesive polymer by solvent casting or melting 
(in the case of hot-melt adhesives) on an impervious backing 
layer. On top of the reservoir, unmediated adhesive polymer 
layers are applied for protection purpose. 
ii. Matrix-dispersion system: 
In this type the drug is dispersed homogenously in a 
hydrophilic or lipophilic polymer matrix. This drug 
containing polymer disk is fixed on to an occlusive base 
plate in a compartment fabricated from a drug impermeable 
backing layer. Instead of applying the adhesive on the face of 
the drug reservoir, it is spread along with the circumference 
to form a strip of adhesive rim. 
f) Microreservoir system: 
In this type the drug delivery system is a combination of 
reservoir and matrix-dispersion system. The drug reservoir is 
formed by first suspending the drug in an aqueous solution of 
water soluble polymer and then dispersing the solution 
homogeneously in a lipophilic polymer to form thousands of 
unreachable, microscopic spheres of drug reservoirs. This 
thermodynamically unstable dispersion is stabilized quickly 
by immediately cross-linking the polymer in situ by using 
cross linking agents. 
Shingade et al                          Journal of Drug Delivery & Therapeutics; 2012, 2(1)   72 
© 2011, JDDT. All Rights Reserved                                                                                                                                                                      ISSN: 2250-1177 
VARIOUS METHODS FOR PREPARATION TDDS: 
a. Asymmetric TPX membrane method: 
23
 
A prototype patch can be fabricated for this a heat sealable 
polyester film (type 1009, 3m) with a concave of 1cm 
diameter will be used as the backing membrane. Drug sample 
is dispensed into the concave membrane, covered by a TPX 
{poly(4-methyl-1-pentene)}asymmetric membrane, and 
sealed by an adhesive. 
b. Circular teflon mould method:
24
  
Solutions containing polymers in various ratios are used in 
an organic solvent. Calculated amount of drug is dissolved in 
half the quantity of same organic solvent. Enhancers in 
different concentrations are dissolved in the other half of the 
organic solvent and then added. Di-N-butylphthalate is added 
as a plasticizer into drug polymer solution. The total contents 
are to be stirred for 12 hrs and then poured into a circular 
teflon mould. The moulds are to be placed on a leveled 
surface and covered with inverted funnel to control solvent 
vaporization in a laminar flow hood model with an air speed 
of 0.5 m/s. The solvent is allowed to evaporate for 24 hrs. 
The dried films are to be stored for another 24 hrs at 
25±0.5°C in a desiccators containing silica gel before 
evaluation to eliminate aging effects. The type films are to be 
evaluated within one week of their preparation. 
c. Mercury substrate method:
25
 
In this method drug is dissolved in polymer solution along 
with plasticizer. The above solution is to be stirred for 10-15 
minutes to produce a homogenous dispersion and poured in 
to a leveled mercury surface, covered with inverted funnel to 
control solvent evaporation.  
d. By using   IPM membranes” method:26   
In this method drug is dispersed in a mixture of water and 
propylene glycol containing carbomer 940 polymer and 
stirred for 12 hrs in magnetic stirrer. The dispersion is to be 
neutralized and made viscous by the addition of 
triethanolamine. Buffer pH 7.4 can be used in order to obtain 
solution gel, if the drug solubility in aqueous solution is very 
poor. The formed gel will be incorporated in the IPM 
membrane. 
e. By using   EVAC membranes” method: 27 
In order to prepare the target transdermal therapeutic system, 
1% carbopol reservoir gel, polyethelene (PE), ethylene vinyl 
acetate copolymer (EVAC) membranes can be used as rate 
control membranes. If the drug is not soluble in water, 
propylene glycol is used for the preparation of gel. Drug is 
dissolved in propylene glycol; carbopol resin will be added 
to the above solution and neutralized by using 5% w/w 
sodium hydroxide solution. The drug (in gel form) is placed 
on a sheet of backing layer covering the specified area. A 
rate controlling membrane will be placed over the gel and the 
edges will be sealed by heat to obtain a leak proof device. 
f. Aluminium backed adhesive film method: 
28        
Transdermal drug delivery system may produce unstable 
matrices if the loading dose is greater than 10 mg.Aluminium 
backed adhesive film method is a suitable one. For 
preparation of same, chloroform is choice of solvent, because 
most of the drugs as well as adhesive are soluble in 
chloroform. The drug is dissolved in chloroform and 
adhesive material will be added to the drug solution and 
dissolved. A custam made aluminium former is lined with 
aluminium foil and the ends blanked off with tightly fitting 
cork blocks.  
g. Preparation of TDDS by using Proliposomes:
29,30                  
The proliposomes are prepared by carrier method using film 
deposition technique. From the earlier reference drug and 
lecithin in the ratio of 0.1:2.0 can be used as an optimized 
one. The proliposomes are prepared by taking 5mg of 
mannitol powder in a 100 ml round bottom flask which is 
kept at 60-70°c temperature and the flask is rotated at 80-90 
rpm and dried the mannitol at vacuum for 30 minutes. After 
drying, the temperature of the water bath is adjusted to 20-
30°C. Drug and lecithin are dissolved in a suitable organic 
solvent mixture, a 0.5ml aliquot of the organic solution is 
introduced into the round bottomed flask at 37°C, after 
complete drying second aliquots (0.5ml) of the solution is to 
be added. After the last loading, the flask containing 
proliposomes are connected in a lyophilizer and subsequently 
drug loaded mannitol powders proliposomes) are placed in a 
desiccator over night and then sieved through 100 mesh. The 
collected powder is transferred into a glass bottle and stored 
at the freeze temperature until characterization. 
h. By using free film method:
 31
 
Free film of cellulose acetate is prepared by casting on 
mercury surface. A polymer solution 2% w/w is to be 
prepared by using chloroform. Plasticizers are to be 
incorporated at a concentration of 40% w/w of polymer 
weight. Five ml of polymer solution was poured in a glass 
ring which is placed over the mercury surface in a glass petri 
dish. The rate of evaporation of the solvent is controlled by 
placing an inverted funnel over the Petri dish. The film 
formation is noted by observing the mercury surface after 
complete evaporation of the solvent. The dry film will be 
separated out and stored between the sheets of wax paper in a 
desiccator until use. Free films of different thickness can be 
prepared by changing the volume of the polymer solution. 
EVALUATION PARAMETERS: 
1. Interaction studies: 
31, 32
 
Excipients are integral components of almost all 
pharmaceutical dosage forms. The stability of a formulation 
amongst other factors depends on the compatibility of the 
drug with the excipients. The drug and the excipients must be 
compatible with one another to produce a product that is 
stable, thus it is mandatory to detect any possible physical or 
chemical interaction as it can affect the bioavailability and 
stability of the drug. If the excipients are new and have not 
been used in formulations containing the active substance, 
the compatibility studies play an important role in 
formulation development. Interaction studies are commonly 
carried out in Thermal analysis, FT-IR, UV and 
chromatographic techniques by comparing their 
Shingade et al                          Journal of Drug Delivery & Therapeutics; 2012, 2(1)   73 
© 2011, JDDT. All Rights Reserved                                                                                                                                                                      ISSN: 2250-1177 
physicochemical characters susuch as assay, melting 
endotherms, characteristic wave numbers, absorption 
maxima etc., 
2. Thickness of the patch: 
33
   
The thickness of the drug loaded patch is measured in 
different points by using a digital micrometer and determines 
the average thickness and standard deviation for the same to 
ensure the thickness of the prepared patch. 
3. Weight uniformity: 
33   
The prepared patches are to be dried at 60°c for 4hrs before 
testing. A specified area of patch is to be cut in different 
parts of the patch and weigh in digital balance. The average 
weight and standard deviation values are to be calculated 
from the individual weights. 
4. Folding endurance:
 33  
A strip of specific are is to be cut evenly and repeatedly 
folded at the same place till it broke. The number of times 
the film could be folded at the same place without breaking 
gave the value of the folding endurance. 
5. Percentage Moisture content: 
33
 
The prepared films are to be weighed individually and to be 
kept in a desiccator Containing fused calcium chloride at 
room temperature for 24 hrs. After 24 hrs the films are to be 
reweighed and determine the percentage moisture content 
from the below mentioned formula. Percentage moisture 
content = [Initial weight- Final weight/ Final weight] ×100. 
6. Percentage Moisture uptake: 
33  
The weighed films are to be kept in a desiccator at room 
temperature for 24 hrs containing saturated solution of 
potassium chloride in order to maintain 84% RH. After 24 
hrs the films are to be reweighed and determine the 
percentage moisture uptake from the below mentioned 
formula.Percentage moisture uptake = [Final weight- Initial 
weight/ initial weight] ×100. 
7. Water vapour permeability (WVP) evaluation: 
32   
Water vapour permeability can be determined with foam 
dressing method the air forced oven is replaced by a natural 
air circulation oven. The WVP can be determined by the 
following formula  WVP=W/A Where, WVP is expressed in 
gm/m2 per 24hrs, W is the amount of vapour permeated 
through the patch expressed in gm/24hrs and A is the surface 
area of the exposure samples expressed in m2.  
8. Drug content: 
32
 
A specified area of patch is to be dissolved in a suitable 
solvent in specific volume. Then the solution is to be filtered 
through a filter medium and analyse the drug contain with 
the suitable method (UV or HPLC technique). Each value 
represents average of three different samples. 
9. Uniformity of dosage unit test: 
33  
An accurately weighed portion of the patch is to be cut into 
small pieces and transferred to a specific volume volumetric 
flask, dissolved in a suitable solvent and sonicate for 
complete extraction of drug from the patch  and made up to 
the mark with same. The resulting solution was allowed to 
settle for about an hour, and the supernatant was suitably 
diluted to give the desired concentration with suitable 
solvent. The solution was filtered using 0.2 m membrane 
filter and analysed by suitable analytical technique (UV or 
HPLC) and the drug content per piece will be calculated. 
10. Polariscope examination: 
33 
This test is to be performed to examine the drug crystals 
from patch by polariscope. A specific surface area of the 
piece is to be kept on the object slide and observe for the 
drugs crystals to distinguish whether the drug is present as 
crystalline form or amorphous form in the patch. 
11. Shear Adhesion test: 
33
 
This test is to be performed for the measurement of the 
cohesive strength of an adhesive polymer. It can be 
influenced by the molecular weight, the degree of 
crosslinking and the composition of polymer, type and the 
amount of tackifier added. An adhesive coated tape is applied 
onto a stainless steel plate; a specified weight is hung from 
the tape, to affect it pulling in a direction parallel to the plate. 
Shear adhesion strength is determined by measuring the time 
it takes to pull the tape off the plate. The longer the time take 
for removal, greater is the shear strength. 
12. Peel Adhesion test: 
33    
In this test, the force required to remove an adhesive coating 
form a test substrate is referred to as peel adhesion. 
Molecular weight of adhesive polymer, the type and amount 
of additives are the variables that determined the peel 
adhesion properties. A single tape is applied to a stainless 
steel plate or a backing membrane of choice and then tape is   
Pulled from the substrate at a 180º angle, and  the force 
required for tape removed is measured. Peel adhesion is the 
force required to remove an adhesive coating from a test 
substrate. Adhesive should provide adequate contact of the 
device with the skin and should not damage the skin on 
removal. Peel adhesion properties are affected by the 
molecular wt of the adhesive polymer, the type and amount 
of additives, and polymer composition. It is tested by 
measuring the force required to pull a single coated tape, 
applied to a substrate, at a 1800 angle. No residue on the 
substrate indicates ‘adhesive failure’ which is desirable for 
transdermal devices. Remnants on the substrate indicate 
‘cohesive failure’ signifying a deficit of cohesive strength in 
the coating. 
13. Thumb tack test: 
It is a qualitative test applied for tack property determination 
of adhesive. The thumb is simply pressed on the adhesive 
and the relative tack property is detected. 
14. Flatness test: 
34
 
Three longitudinal strips are to be cut from each film at 
different portion like one from he center, other one from the 
left side, and another one from the right side. The length of 
each strip was measured and the variation in length because 
of non-uniformity in flatness was measured by determining 
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percent constriction, with 0% constriction equivalent to 
100% flatness. 
15. Percentage Elongation break test: 
35
   
The percentage elongation break is to be determined by 
noting the length just before the reak point, the percentage 
elongation can be determined from the below mentioned 
formula. Elongation percentage = L1-L2 ×100 L2 .Where, 
L1is the final length of each strip and L2 is theinitial length 
of each strip. 
16. Rolling ball tack test: 
36 
This test measures the softness of a polymer that relates to 
talk. In this test, stainless steel ball of 7/16 inches in diameter 
is released on an inclined track so that it rolls down and 
comes into contact with horizontal, upward facing adhesive. 
The distance the ball travels along the adhesive provides the 
measurement of tack, which is expressed in inch. 
17. Quick Stick (peel-tack) test: 
36 
In this test, the tape is pulled away from the substrate at 90ºC 
at a speed of 12 inches/min. The peel force required to break 
the bond between adhesive and substrate is measured and 
recorded as tack value, which is expressed in ounces or 
grams per inch width. 
18. Probe Tack test: 
36 
In this test, the tip of a clean probe with a defined surface 
roughness is brought into contact with adhesive, and when a 
bond is formed between probe and adhesive. The subsequent 
removal of the probe mechanically breaks it. The force 
required to pull the probe away from the adhesive at fixed 
rate is recorded as tack and it is expressed in grams. 
19. In vitro drug release studies: 
37 
The paddle over disc method (USP apparatus V) can be 
employed for assessment of the release of the drug from the 
prepared patches. Dry films of known thickness is to be cut 
into definite shape, weighed, and fixed over a glass plate 
with an adhesive. The glass plate was then placed in a 500-
mL of the dissolution medium or phosphate buffer (pH 7.4), 
and the apparatus was equilibrated to 32± 0.5°C. The paddle 
was then set at a distance of 2.5 cm from the glass plate and 
operated at a speed of 50 rpm. Samples (5- mL aliquots) can 
be withdrawn at appropriate time intervals up to 24 h and 
analyzed by UV spectrophotometer or HPLC. The 
experiment is to be performed in triplicate and the mean 
value can be calculated. 
20. In vitro skin permeation studies: 
37  
An in vitro permeation study can be carried out by using 
diffusion cell. Full thickness abdominal skin of male Wistar 
rats of weighing 200 to 250g. Hair from the abdominal 
region is to be removed carefully by using a electric clipper; 
the dermal side of the skin was thoroughly cleaned with 
distilled water to remove any adhering tissues or blood 
vessels, equilibrated for an hour in dissolution medium or 
phosphate buffer pH 7.4 before starting the experiment and 
was placed on a magnetic stirrer with a small magnetic 
needle for uniform distribution of the diffusant. The 
temperature of the cell was maintained at 32 ± 0.5°C using a 
thermostatically controlled heater. The isolated rat skin piece 
is to be mounted between the compartments of the diffusion 
cell, with the epidermis facing upward into the donor 
compartment. Sample volume of definite volume is to be 
removed from the receptor compartment at regular intervals, 
and an equal volume of fresh medium is to be replaced. 
Samples are to be filtered through filtering medium and can 
be analyzed spectrophotometrically or HPLC. Flux can be 
determined directly as the slope of the curve between the 
steady-state values of the amount of drug permeated (mg cm-
2) vs. time in hours and permeability coefficients were 
deduced by dividing the flux by the initial drug load (mg cm-
2).  
21. Skin Irritation study: 
33 
Skin irritation and sensitization testing can be performed on 
healthy rabbits (average weight 1.2 to 1.5 kg). The dorsal 
surface (50cm2) of the rabbit is to be cleaned and remove the 
hair from the clean dorsal surface by shaving and clean the 
surface by using rectified spirit and the representative 
formulations can be applied over the skin. The patch is to be 
removed after 24 hr and the skin is to be observed and 
classified into 5 grades on the basis of the severity of skin 
injury. 
22. Stability studies: 
37 
Stability studies are to be conducted according to the ICH 
guidelines by storing the TDDS samples at 40±0.5°c and 
75±5% RH for 6 months. The samples were withdrawn at 
0, 30, 60, 90 and 180 days and analyze suitably for the drug 
content. 
CONCLUSION 
This article provides an valuable information regarding the 
transdermal drug delivery systems and its evaluation process. 
The foregoing shows that TDDS have great potentials, being 
able to use for both hydrophobic and hydrophilic active 
substance into promising deliverable drugs. To optimize this 
drug delivery system, greater understanding of the different 
mechanisms of biological interactions, and polymer are 
required. TDDS a realistic practical application as the next 
generation of drug delivery system 
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